Project Grant R43CA278604
Award Date
9/7/22
Completion Date
8/31/23
Dollars Obligated
$1.8M
Federal Agency
National Cancer Institute
Awardee
Pathware Inc. (NC5PBWCNX956)
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98121, USA
Similar Awards
This $255,991 National Science Foundation project grant supports the development of an automated system for rapid analysis of biopsy samples by Amcyt, Inc. The system aims to increase the efficiency and accessibility of fine needle aspiration biopsy procedures through three automated processes: sample smearing, staining, and image capture. This addresses a critical need to improve biopsy analytics and potentially eliminate up to 20% of failed procedures due to sampling errors. By automating...
This Project Grant award of $593,383, funded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of an AI-augmented, multimodal, label-free nonlinear optical microscopy system for rapid and precise diagnosis of thyroid cancer and lymph node metastasis. The proposed system combines coherent anti-Stokes Raman scattering microscopy, second harmonic generation microscopy, and two-photon autofluorescence microscopy...
The federal Project Grant award of $249,000 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" program (CFDA 93.286) supports the development of a high-throughput photoacoustic histology platform for intraoperative pathological diagnosis. The project aims to create an ultrafast reflection-mode ultraviolet photoacoustic microscopy (UV-PAM) system using structured...
This $683,089 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports research to develop a deep learning-based solution, called DeepLIIF, for more accurate and reproducible immunohistochemistry (IHC) scoring of the PD-L1 biomarker in tumor and immune cells. The project aims to integrate PD-L1 IHC scoring with multiplex immunofluorescence (mIHC) data to improve interpretability and clinical prediction of...
The National Science Foundation awarded a $275,000 Project Grant to Oraliva, Inc. under the Technology, Innovation, and Partnerships program to develop a portable, programmable single cell cytology platform for the early detection of epithelial cancers. The platform will combine microfluidics and artificial intelligence to classify potentially cancerous tissue in near real-time through multiparameter single-cell analysis and automated evaluation. The objectives are to link different clinical...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Macula Vision Systems Inc., a for-profit organization, supports the development of a novel microscopy platform to automate the interpretation of microbiology lab tests performed in hospitals. The project aims to address the shortage of trained lab technicians by engineering a specialized light source, customized camera, and AI-enabled algorithms to analyze...
The National Cancer Institute (NCI) awarded a $1,280,908 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Exai Bio Inc., a small disadvantaged business located in Palo Alto, California. The award period runs from September 12, 2024 to August 31, 2026. The purpose of this Project Grant is to develop a novel assay and artificial intelligence (AI) model for the early detection of non-small cell lung cancer (NSCLC) and predicting its subtypes using a novel...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Loma Linda University provides $710,656 to develop a multi-stage, multi-modal "PROSPECT" tool for risk stratification of oral premalignant lesions (OPLs) and early detection of oral cavity squamous cell carcinoma (OSCC). The key products and services include: Training deep learning models using cytology and histology data to predict OPL progression risk Validating...
This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), aims to develop a point-of-care instrument for rapid, non-destructive assessment of bone marrow aspiration sample adequacy. The $1,074,143 award to Cellia Science, Inc. will fund the transition of a deep-ultraviolet microscopy technology to a commercial-grade device. This...
This $679,188 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) aims to develop liquid biopsy tools using artificial intelligence-assisted isolation of tumor cells from malignant effusions to evaluate known biomarkers and discover new predictive biomarkers and drug targets for metastatic breast cancer. The project will first validate the DeepCell AI-assisted platform to isolate circulating tumor cells from malignant effusions, then use...